SCHEDULE 13G: L1 Capital Global Opportunities Master Fund Discloses 7.59% Stake in Aptevo Therapeutics Inc.
Beneficial Ownership Report
L1 Capital Global Opportunities Master Fund, Ltd. has reported a 7.59% beneficial ownership stake in Aptevo Therapeutics Inc., holding 421,000 shares of common stock.
Summary
- L1 Capital Global Opportunities Master Fund, Ltd. has filed a Schedule 13G, indicating beneficial ownership of Aptevo Therapeutics Inc. common stock.
- The fund beneficially owns 421,000 shares of Aptevo Therapeutics Inc. common stock.
- This ownership represents 7.59% of the total class of common stock outstanding.
- The percentage is calculated based on 5,547,214 common shares outstanding immediately after a recent offering, as per the Issuer's Prospectus Supplement filed on April 22, 2025.
- The filing states that the amounts do not include 400,000 Warrants, which are subject to a 4.99% beneficial ownership limitation.
- L1 Capital Global Opportunities Master Fund, Ltd. holds sole voting power and sole dispositive power over all 421,000 shares.
- David Feldman and Joel Arber are the Directors of L1 Capital Global Opportunities Master Fund, Ltd. and may be deemed to beneficially own these securities, though they disclaim beneficial ownership for other purposes.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership, which is neutral in tone. However, a significant institutional stake can be interpreted as a positive signal by the market.
Positives
- The disclosure of a significant stake (7.59%) by an institutional investor like L1 Capital Global Opportunities Master Fund, Ltd. can be viewed as a vote of confidence in Aptevo Therapeutics Inc.'s future prospects.
- The fund holds sole voting and dispositive power over its shares, indicating a clear and direct investment position.
Future Outlook
This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance from Aptevo Therapeutics Inc. or the reporting person regarding the company's future performance or strategic direction.
Industry Context
This filing indicates an institutional investment in Aptevo Therapeutics Inc., a company operating in the biotechnology and pharmaceutical sector. Such investments reflect investor interest in the potential of companies developing new therapies and drugs, a common trend in the life sciences industry.
Stakeholder Impact
- Shareholders: The disclosure of a new significant institutional holder may influence investor sentiment and potentially the stock price.
- Company Management: Awareness of a large institutional shareholder may influence strategic decisions and communication.
Key Dates
| Date | Description |
|---|---|
| 04/21/2025 | Date of event which requires filing of this statement (beneficial ownership threshold crossed). |
| April 22, 2025 | Date of Issuer's Prospectus Supplement filing under Rule 424(b)(4), used to determine common stock outstanding. |
| 04/25/2025 | Date of filing of the Schedule 13G statement. |
Keywords
Aptevo Therapeutics Inc., L1 Capital Global Opportunities Master Fund, Schedule 13G, beneficial ownership, common stock, institutional investment, biotechnology, pharmaceuticals, equity stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.